Why the study?
Does a rhythm control strategy (using antiarrhythmic drugs and DC cardioversion) improve morbidity or mortality compared to rate control in patients with atrial fibrillation?
Does a rhythm control strategy (using antiarrhythmic drugs and DC cardioversion) improve morbidity or mortality compared to rate control in patients with atrial fibrillation?
Rhythm control offers no morbidity or mortality advantage over rate control in atrial fibrillation, and antiarrhythmic drug selection must be carefully tailored to the presence of structural heart disease.
No takes yet. Share an insight, caveat, or question.
Supports rate control first-line in AF; leaves open need for updated RCTs in contemporary cohorts.
Richard J. Schilling (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: